Philip Bath1, Charles Algert, Neil Chapman, Bruce Neal. 1. Division of Stroke Medicine, Institute of Neuroscience, University of Nottingham, City Hospital Campus, Nottingham NG5 1PB, UK. philip.bath@nottingham.ac.uk
Abstract
BACKGROUND AND PURPOSE: Mean platelet volume (MPV) is positively associated with measures of platelet activity and may be a useful indicator of the risk of vascular events in a variety of patient groups. METHODS: The association of MPV with the risk of stroke was assessed in the Perindopril Protection Against Recurrent Stroke Study (PROGRESS). All participants had a history of cerebrovascular disease at baseline, and analyses were adjusted for the effects of potential confounders. RESULTS: The study followed 3134 individuals for an average of 3.9 years (mean age, 65 years; 71% male; average MPV, 10.0 fL). Three hundred eighty-three individuals had 402 stroke events, and 160 had major coronary events. MPV was positively associated with the risk of stroke, with an 11% increased relative risk (95% CI, 3% to 19%) of stroke per femtoliter greater MPV. There was no clear association of MPV with the risk of major coronary events (9% decreased relative risk; 95% CI, -23% to 7%). Perindopril did not alter MPV. CONCLUSIONS: MPV is an independent predictor of the risk of stroke among individuals with a history of stroke or transient ischemic attack. The measurement of MPV may add useful prognostic information for clinicians managing patients with a history of cerebrovascular disease.
BACKGROUND AND PURPOSE: Mean platelet volume (MPV) is positively associated with measures of platelet activity and may be a useful indicator of the risk of vascular events in a variety of patient groups. METHODS: The association of MPV with the risk of stroke was assessed in the Perindopril Protection Against Recurrent Stroke Study (PROGRESS). All participants had a history of cerebrovascular disease at baseline, and analyses were adjusted for the effects of potential confounders. RESULTS: The study followed 3134 individuals for an average of 3.9 years (mean age, 65 years; 71% male; average MPV, 10.0 fL). Three hundred eighty-three individuals had 402 stroke events, and 160 had major coronary events. MPV was positively associated with the risk of stroke, with an 11% increased relative risk (95% CI, 3% to 19%) of stroke per femtoliter greater MPV. There was no clear association of MPV with the risk of major coronary events (9% decreased relative risk; 95% CI, -23% to 7%). Perindopril did not alter MPV. CONCLUSIONS: MPV is an independent predictor of the risk of stroke among individuals with a history of stroke or transient ischemic attack. The measurement of MPV may add useful prognostic information for clinicians managing patients with a history of cerebrovascular disease.
Authors: Luanne L Peters; Weidong Zhang; Amy J Lambert; Carlo Brugnara; Gary A Churchill; Orah S Platt Journal: Mamm Genome Date: 2005-10-29 Impact factor: 2.957
Authors: Angéline Bertin; Michael C Mahaney; Laura A Cox; Jeffrey Rogers; John L VandeBerg; Carlo Brugnara; Orah S Platt Journal: Mamm Genome Date: 2007-06-08 Impact factor: 2.957
Authors: Christa Meisinger; Holger Prokisch; Christian Gieger; Nicole Soranzo; Divya Mehta; Dieter Rosskopf; Peter Lichtner; Norman Klopp; Jonathan Stephens; Nicholas A Watkins; Panos Deloukas; Andreas Greinacher; Wolfgang Koenig; Matthias Nauck; Christian Rimmbach; Henry Völzke; Annette Peters; Thomas Illig; Willem H Ouwehand; Thomas Meitinger; H-Erich Wichmann; Angela Döring Journal: Am J Hum Genet Date: 2008-12-24 Impact factor: 11.025
Authors: Ozlem Arican Ozluk; Ibrahim Ber; Tezcan Peker; Mustafa Yilmaz; Erhan Tenekecioglu; Kemal Karaagac; Fahriye Vatansever Journal: Int J Clin Exp Med Date: 2015-02-15